Table 1.

Clinical Breakpoints for Antifungal Agents Against Common Candida Species

Candida Organism	Clinical Breakpoint, µg/mLa
	Antifungal Agent	S	SDD	I	R
C. albicans	Fluconazole	≤2	4		≥8
	Itraconazole	≤0.12	0.25–0.5		≥1
	Voriconazole	≤0.12		0.25–0.5	≥1
	Posaconazole
	Anidulafungin	≤0.25		0.5	≥1
	Caspofungin	≤0.25		0.5	≥1
	Micafungin	≤0.25		0.5	≥1
C. glabrata	Fluconazole		32		≥64
	Itraconazole
	Voriconazole
	Posaconazole
	Anidulafungin	≤0.12		0.25	≥0.5
	Caspofungin	≤0.12		0.25	≥0.5
	Micafungin	≤0.06		0.12	≥0.25
C. parapsilosis	Fluconazole	≤2	4		≥8
	Itraconazole
	Voriconazole	≤0.12		0.25–0.5	≥1
	Posaconazole
	Anidulafungin	≤2		4	≥8
	Caspofungin	≤2		4	≥8
	Micafungin	≤2		4	≥8
C. tropicalis	Fluconazole	≤2	4		≥8
	Itraconazole
	Voriconazole	≤0.12		0.25–0.5	≥1
	Posaconazole
	Anidulafungin	≤0.25		0.5	≥1
	Caspofungin	≤0.25		0.5	≥1
	Micafungin	≤0.25		0.5	≥1
C. krusei	Fluconazole
	Itraconazole
	Voriconazole	≤0.5		1	≥2
	Posaconazole
	Anidulafungin	≤0.25		0.5	≥1
	Caspofungin	≤0.25		0.5	≥1
	Micafungin	≤0.25		0.5	≥1

Where no values are entered, there are insufficient data to establish clinical breakpoints.

Abbreviations: I, intermediate; MIC, minimum inhibitory concentration; R, resistant; S, susceptible; SDD, susceptible dose-dependent.

^a Clinical breakpoints adopted by the Clinical and Laboratory Standards Institute.